BioSpace News Archive

The shareholders of Medivir AB, reg. no. 556238-4361, with its registered office in Huddinge, Stockholm, are hereby summoned to the extraordinary general meeting on Wednesday 13 January 2021.

The San Diego office of American Specialty Health Incorporated has been named among San Diego’s “Top Workplaces” in the 8th annual Top Workplaces awards sponsored by the San Diego Union Tribune and Philadelphia-based Energage.

Ohio State University’s Chief of Colon and Rectal Surgery joins Advisory Board at surgical intelligence startup focused on democratizing surgical care

Winning researchers and startup entrepreneurs capture prizes in four categories at Oregon Bio Digital 2020: Amplifying Diversity of Discovery, Access and Economics conference

The GP2 Phase III clinical trial design was presented during the 2020 San Antonio Breast Cancer Symposium (SABCS) and introduced by the Global Principal Investigator, Professor Mothaffar F. Rimawi of Baylor College of Medicine

Kintor Pharmaceutical Limited (HKEX: 9939) is pleased to update the preliminary analysis of the Proxalutamide’s clinical trial for COVID-19.

The board of directors of Pfizer Inc. (NYSE:PFE) declared a 39-cent first-quarter 2021 dividend on the company’s common stock, payable March 5, 2021, to holders of the Common Stock of record at the close of business on January 29, 2021.

Prevail Therapeutics Inc. (Nasdaq: PRVL), a biotechnology company developing potentially disease-modifying AAV-based gene therapies for patients with neurodegenerative diseases, today announced that the first patient has been dosed in the Phase 1/2 PROCLAIM clinical trial evaluating PR006, an investigational AAV9 gene therapy delivering the GRN gene, for the treatment of frontotemporal dementia patients with GRN mutations (FTD-GRN).

Swedish Orphan Biovitrum AB (publ) (Sobi™) (STO:SOBI) today announces that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion of Doptelet® (avatrombopag) for the treatment of primary chronic immune thrombocytopenia (ITP) in adult patients who are refractory to other treatments (e.g. corticosteroids, immunoglobulins)

PureTech Health plc (LSE: PRTC, Nasdaq: PRTC) (“PureTech” or the “Company”), a clinical-stage biotherapeutics company dedicated to discovering, developing and commercializing highly differentiated medicines for devastating diseases, today announced the initiation of its Phase 1 clinical trial of LYT-200 for the potential treatment of metastatic solid tumors that are difficult to treat and have poor survival rates.